Clinical observation of osimertinib combined with bevacizumab in the treatment of patients with advanced lung adenocarcinoma and EGFR T790M mutation
Objective To explore the clinical observation of osimertinib(AZD9291)combined with bevacizumab in the treatment of patients with advanced lung adenocarcinoma and epidermal growth factor receptor(EGFR)T790M mutation.Methods A total of 96 patients with advanced lung adenocarcinoma and EGFR T790M mutation who were confirmed by pathological examination and gene detection in the hospital were enrolled between January 2020 and June 2023.According to dynamic randomization method,they were divided into the control group(n=48,osimertinib)and the observation group(n=48,bevacizumab combined with osimertinib).The short-term and long-term curative effect,serum indexes[carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),vascular endothelial growth factor(VEGF)]and adverse reactions were compared between the two groups.Results The short-term curative effect in the observation group was significantly better than that in the control group(P＜0.05).The progression rate and mortality in the observation group were all lower than those in the control group(P＜0.05),and progression-free survival was longer than that in the control group(P＜0.05).After treatment,levels of CA125,CEA and VEGF in the observation group were lower than those in the control group(P＜0.05).There was no significant difference in incidence of anemia,hypertension,proteinuria and rash between the two groups(P＜0.05).Conclusion Bevacizumab combined with osimertinib can improve short-term and long-term curative effect,and reduce levels of tumor markers in patients with advanced NSCLC and EGFR T790M mutation,which will not increase the risk of adverse reactions.
NETL
NSTL
万方数据
